Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MA-BUCY2 vs BUCY2 Conditioning for Haplo-HSCT in High-Risk AML
NCT05814731Not yet recruiting
- Sponsor
- First Affiliated Hospital of Xi'an Jiaotong University
- Start
- Apr 2023
- Primary completion
- Dec 2025
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Randomised, open-label trial of mitoxantrone-liposome in acute myeloid leukemia (AML) (2 arms), sponsored by First Affiliated Hospital of Xi'an Jiaotong University. Primary endpoint: Relapse Rates at 1 year. Planned start Apr 2023; status: not yet recruiting.
02
Drugs
mitoxantrone-liposome
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05814731.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05814731.